Obrador GT, et al. 347). Bogart M, Chastek B, White J, et al. [Oral presentation available here; Abstract A6247]. Did this answer your question? om ons te informeren over dit probleem. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 14. Click the link in the email we sent to to verify your email address and activate your job alert. Our employees and our values are at the heart of everything we do. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States ? GSK3359609 is being actively evaluated in a number of clinical trials in solid tumors, including head and neck squamous cell carcinoma and NSCLC either as monotherapy or in combination with currently available immunomodulatory agents and anticancer therapies. POSTER: Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post-hoc analysis from the GARNET trial, 2. Poly ADP ribose polymerases (PARPs) are a family of enzymes involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. P1488. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. We use cookies to personalise content and ads, to provide social media features and to analyse our websites. 6. 4. This number represents the median, which is the midpoint of the ranges from our proprietary Total Pay Estimate model and based on salaries collected from our users. ORAL PRESENTATION: Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer, 2. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. All rights reserved. CD96 is an immune checkpoint that regulates CD8+ T-cell antitumor function. Rates of Major Events in Untreated Patients Diagnosed ?With Anemia of CKD in France?? Pollard S, Offenberger J, Lee FE-H, et al. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. POSTER: Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial vs an external control arm from the Flatiron Health database, 9. Bell CF, et al. It inspires every one of us to do our best work. POSTER: Year 4 Observational Follow up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE who Completed a Phase 4, 52-week, Randomised, Double-blind Placebo-controlled Safety, 4. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. Ismaila A, Haeussler K, Czira A, et al. GSK US Medical Affairs Scientific Director, Specialty Pipeline Durham, NC 30d+ $95K-$138K Per Year (Glassdoor est.) Poster No. Watch the video here: gsk.to/3KQpI7P, Today is the day! Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer, 1. 6. takebackday.dea.govw The Effect of Belimumab on Kidney Outcomes in SLE: Results of a Large Integrated Analysis, 4. 3. Presented at: European Hematology Association (EHA) Annual Meeting; June 13-16, 2019; Amsterdam, Netherlands. [Poster No. [Poster No. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. 1. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons, 16. Intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab For COVID-19, 1. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO). POSTER: Immuno-PET monitoring of CD8 + T cell infiltration post anti-ICOS agonist antibody treatment alone and in combination with PD-1 blocking antibody using a 89Zr anti-CD8+ mouse minibody in EMT 6 syngeneic tumor mouse, 4. and PD-L1, for Second-Line (2L) Treatment of Non-Small Cell Lung Cancer (NSCLC). 3888792. Caso continue recebendo esta mensagem, Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD? Seo J, Zhang S, Krucien N, et al. Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) ? 1. Silver J, Bogart M, Molfino N, et al. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Singh AK, et al. Immune checkpoints and their inhibition in cancer and infectious diseases. 14. Slade D, Ray R, Moretz C, et al. P813; Abstract A4302]. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. Vaccine Temperature Poulard C, Corbo L, Le Romancer M. Protein arginine methylation/demethylation and cancer. Criner GJ, Barnes N, Brusselle G, et al. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. P824; Abstract A4313]. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Two Clinical Trials, 7. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. 1. New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and cancer-testis antigen 2 (LAGE-1a) are immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. 1. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of 6 Trials, 9. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. Hwee J, Smith S, Small M, et al. 115 Medical Affairs Gsk jobs available on Indeed.com. Trade marks are owned by or licensed to the GSK group of companies. We are committed to doing the right thing: our ambition is to improve the lives of billions across the world. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. 2. 2. Wir entschuldigen uns fr die Umstnde. POSTER: Phase 2 platform trial of anti-T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) GSK?859A/EOS-448 plus anti-programmed death-1 (PD-1) dostarlimab in patients with non-small cell lung cancer (NSCLC), 1. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 3. Association between TGF-? This site is intended for US Healthcare Professionals. To report suspected adverse reactions, please call us at The products discussed may have different product labeling in different countries. Silver J, Strobel MJ, Gratie D, et al. 4. PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. 8. 2. POSTER: Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs), 10. A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States (ESGO Encore), 3. Chupp G, Heaney LG, Pelaia G, et al. 1. POSTER: A first-in-clinic phase 1 study of GSK3745417 STING agonist in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, 1. Gsk Medical Jobs in London | Indeed.com POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM], 2. Lee F, Liu M, Bagnasco D, et al. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. [Poster No. J Clin Oncol. naar Plain Language Summary [HCP USE ONLY]: GARNET: Results on Dostarlimab in Patients with Recurrent or Advanced dMMR Endometrial Cancer (PROs), 1. 3. 3. Home | GSK US GSK Director, US Medical Affairs, Adult Immunization and Health Equity Durham, NC 30d+ $71K-$112K Per Year (Glassdoor est.) We're committed to doing the right thing for the people who count on us, and our culture will help you deliver what matters most - better and faster. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. This medical information is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE), 11. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. ORAL PRESENTATION: Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer, 1. POSTER: Phase 2 study of anti-TIGIT GSK4428859A (GSK?859A)/EOS-448 + anti-CD96 GSK6097608 (GSK?608) + anti?PD-1 dostarlimab in non-small cell lung cancer (NSCLC), 1.POSTER: Prevalence and clinical characteristics of metastatic synovial sarcoma (mSS) patients with tumours expressing NY-ESO-1 antigen (NY+) and who are HLA-A*02:01, *02:05 or *02:06 allele positive (HLA+): Cohort study from the French Sarcoma Group (Presentation Posted With Permission), 1.POSTER: NIRVANA-1: A multicentric randomized trial to compare carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP?bevacizumab (bev) followed by nira-bev in patients with stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery (Presentation Posted With Permission), 1. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in driving necroptosis, a proinflammatory form of cell death that may promote metastasis and suppress T-cell?driven antitumor immunity. Strong industry experience, spanning clinical development and medical affairs. per informarci del problema. ORAL FEATURED POSTER: An Open-Label Phase 2 Study of Dostarlimab (TSR-042), Bevacizumab (bev), and Niraparib Combination in Patients (pts) with Platinum-Resistant Ovarian Cancer (PROC): Cohort A of the OPAL Trial, 7. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial, 2. London - Brentford, USA - Pennsylvania - Upper Providence Posted Date: Mar 6 2023 Job Purpose * Key member of the Rheumatology Global Medical team. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. The response(s) are not intended to offer recommendations for administering this product in a manner inconsistent with its approved labeling. Bogart M, Han X, Bengtson L, et al. . POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. 64), 5. We support smart risk-taking while doing the right thing, invest in innovation where and when it matters, and constantly strive to do things better to make an impact on peoples health across the world. 1. 1. 2017;35(15):suppl TPS3113. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. Single-agent Belantamab Mafodotin for RRMM: Analysis of the Lyophilized Presentation Cohort from the Pivotal DREAMM-2 Study [Poster not available for viewing due to copyright restrictions], 9. P1445. Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018. GSK plc. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. This information does not take the place of talking with your doctor. 2017;31(2):101-1261. Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor ? Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. 2. POSTER: Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment, 3. This resource may include information that has not been approved by the US Food and Drug Administration. Singer D et al. 1. Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians. Kerwin EM, Maltais F, Boucot IH, et al. David Brooks - Vice President, Country Medical Director, UK - LinkedIn POSTER: Belantamab Mafodotin (GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics in DREAMM-2, 8. Areas, Search Medical 1. 2015;5:34, Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Initiating Mepolizumab. Assessment of Asthma Control in Respiratory Specialist Offices in the US. Poster No. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial (AACR ENCORE), 9. 4. ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (2017?2020), 1. ORAL PRESENTATION: Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY), 1. The most rewarding part about working at GSK is that I know I can count on my team and leadership for guidance and support. Sie weiterhin diese Meldung erhalten, informieren Sie uns darber bitte per E-Mail PO0465, ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. PUBLICATION ONLY: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting, 23. [Oral presentation available here; Abstract A4211]. April 27, 2023. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. 2. J Clin Invest. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. GSK6097608 inhibits the binding of CD96 to CD155 and activates T cells and NK cells, which enhances antitumor activity. Initiating Mepolizumab. P1454. perspective on the burden of Hypereosinophilic Syndrome. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. [Poster No. Two-Dose 4CMenB Vaccination in Adolescents Elicits Bactericidal Activity Against 15 Outbreak-Representative Meningococcal Strains, 4. Causes of Death in Patients with Anemia of ?Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial. 1. Real-World Insights on the Burden of Hypereosinophilic ?Syndrome (HES)?. The science of giving Strobel M, Alves D, Roufosse F, et al. Goodall E, Wood R, Numbere B, et al. It is being investigated as monotherapy and in combination with other anticancer agents in various malignancies. Kickstart your career at GSK by applying to any one of our Early Talent Programmes programmes. ORAL FEATURED POSTER: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 5. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 15. McCormack E, Adams KJ, Hassan NJ, et al. This is our global website, intended for visitors seeking information on GSK's worldwide business. The information you are about to be referred to may not comply with the local regulatory requirements. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. ORAL FEATURED POSTER: Interim Analysis of the Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer Cohorts From the GARNET Study, 1. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. (Poster No. 1. 1. 346). Real World Immuno-oncology Treatment Patterns and Outcomes in US Patients with Metastatic Head and Neck Cancer, Presentation: DREAMM-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-Directed Immunoconjugate) in Combination With Novel Agents in Relapsed/Refractory Multiple Myeloma (RRMM), Presentation: DREAMM-2: Pivotal Study Primary Analysis: Single-Agent Belantamab Mafodotin (GSK2857916) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors (PIs), Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), DREAMM-2: Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory/Intolerant to Anti-CD38 mAb, Including Subgroups With Renal Impairment (RI) and High-Risk (HR) Cytogenetics, Safety and Efficacy of Anti-PD-1 Antibody Dostarlimab in Patients with Mismatch Repair-Deficient (dMMR) GI Cancers, 1. P1501. Schwarz TF et al. The estimated total pay for a Medical Affairs at GSK is $206,808 per year. The estimated total pay for a Medical Science Liaison at GSK is $234,850 per year. Analysis of Co-Resistance Among Klebsiella pneumoniae Urine Isolates From Female Outpatients in the United States. Visit Brain Metastases in Primary Ovarian Cancer: Real-world Data, 1. You can unsubscribe from these emails at any time. . Women in science Beth's mission is to make a molecule that becomes medicine while helping others succeed. Disculpa Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. We're taking on some of the biggest healthcare challenges in . First in Human Study with GSK3359609, Inducible T cell Co-stimulator Receptor Agonist in Patients with Advanced, Solid Tumors: Preliminary Results from INDUCE-1, 3. Han MK, Bratton DJ, Hartley B, et al. Singh, AK et al. 11. 7. 336), 1. 8. ORAL PRESENTATION: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 1. 1. Medical Affairs Gsk Jobs - 2022 | Indeed.com Can we break that record on Sat 4/22? Moretz C, Hahn B, White J, et al. This number represents the median, which is the midpoint of the ranges from our proprietary Total Pay Estimate model and based on salaries collected from our users. CAPTAIN: Effects of age as a continuous variable on asthma control. Dostarlimab is being investigated as a monotherapy in DNA mismatch repair?deficient cancers, including endometrial cancer, and in unselected populations in combination with other therapies. The estimated additional pay is $52,492 per year. © 2022 GSK group of companies or its licensor. Patients? Knudson KM, Hicks KC, Luo X, Chen J-Q, Schlom J, Gameiro SR. M7824, a novel bifunctional anti-PD-L1/TGF trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. 5. Phase 2 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-? POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. NY-ESO-1 based immunotherapy of cancer: current perspectives. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. POSTER: Treatment patterns and time to next treatment among OC patients in a real-life setting in Finland: the OCRWE-Finland study (ASCO Encore), 3. Congrats to the @startupfiu students in the GSK #Innovation Challenge addressing low vaccination rates in the Hispanic community. We are sorry for the inconvenience. Sign In. The product information provided by this site is intended only for health care professionals, patients, consumers and caregivers in the United States. Poster No. 3. GSK is committed to the discovery and development of new vaccines and oncology and hematology compounds that leverage patient-driven science to deliver improved outcomes for more patients. P1458. P786; Abstract A5624]. POSTER: Knowledge of Invasive Meningococcal Disease and Vaccination Recommendations for Adolescents and Young Adults among US Physicians. Blood. Gupte R, Liu Z, Kraus WL. Rothnie KJ, Bancroft T, Bogart M, et al. GSK3377794 is an adoptive cell therapy that uses genetically engineered autologous T cells expressing NY-ESO-1? ViiV (GSK) Global Medical Affairs Director: GSK PLC: London, England: 32K-85K: Medical Director, Healthcare Solutions - Respiratory: GSK PLC: Brentford, England: . Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody, 2. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. Poster No. A Population Study. Find out more: gsk.to/41zwzb7, While everyone can be impacted by #myelofibrosis, certain risk factors can increase the likelihood that a person will develop it.